Salta al menu principale di navigazione Salta al contenuto principale Salta al piè di pagina del sito

Saggi, Studi e Ricerche

N. 55 (2020)

Costo-beneficio del trattamento con i farmaci antivirali ad azione diretta nei consumatori di sostanze con epatite C: una valutazione del percorso di point of care

2 July 2021
08-07-2021 — Aggiornato il 28-07-2021



Hepatitis C is a disease correlated with severe systemic consequences having elevated social and health costs. The HCV elimination is a public health concern that may be solved reaching DAAs treatment for drug users. The principal aim of this work is to evaluate the cost-benefit of a point of care for HCV treatment of drug users inside Drug abuse services (Ser.D.).


The study consists in a cost-benefit analysis able to evaluate the “return of health” induced by a point of care for a HCV treatment.


The work shows that the point of care is cost-benefit in comparison with the “traditional” treatment being cost saving for the public health system. The data suggest that the cost of the point of care is corresponding to euros 593,40 while the cost of not treatment of euros 8.679,60 (due to the direct and indirect costs of the disease).


The study demonstrate the point of care is an effective model of care able to reduce the barriers of treatment and to induce a “health return” in term of cost saving for the public health systems. Indeed, the work shows how the point of care may make the elimination HCV plans sustainable for the public health agencies.

Riferimenti bibliografici

  1. AIFA, Registri AIFA per il monitoraggio dei farmaci anti-HCV (2019).
  2. Alimohsmmadi A., Holrksa J., Thiam A., Truong D., Conway B. (2018). Realword efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs delivered in a multidisciplinary setting. Open Forum Infect Dis., 5/6: ofy120. DOI: 10.1093/ofid/ofy120.
  3. Axelrod D.A., Schnitzler M.A., Alhamad T., Gordon F., Bloom R.D., Hess G.P., Xiao H., Nazzal M., Segev D.L., Dharnidharka V.R., Naik A.S., Lam N.N., Ouseph R., Kasiske B.L., Durand C.M., Lentine K.L. (2018). The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes. Am. J. Transplant., 18(10): 2473-2482. DOI: 10.1111/ajt.14895.
  4. Baio G., Capone A., Marcellusi A., Mennini F.S., Favato G. (2013). Economic burden of human papillomavirus-related diseases in Italy. PLoS One, 7: e49699.
  5. Bajis S., Dore G.J., Hajarizadeh B., Cunningham E.B., Grebely J. (2017). Intervention to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. Int. J. Drug Policy, 47: 34-46.
  6. Barbosa C., Fraser H., Hoeger T.J., Leib A., Havens J.R., Young A., Kral A., Page K., Evans J., Zibell J., Hariri S., Vellozzi C., Nerlander L., Ward J.W., Vickerman P. (2019). Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addiction, 114(12): 2267-2278. DOI: 10.1111/add.14731.
  7. Blach S., Kondili L.A., Aghemo A., Cai Z., Dugan E., Estes C., Gamkreudze I., Ma S., Pawlotsky J.M., Razavi-Shearer D., Razavi H., Waked I., Zeuzem S., Craxi A. (2021). Impact of Covid-19 on global HCV elimination efforts. J. Hepathol., 74(1): 31-36.
  8. Briggs A. (1999). Economics notes: handling uncertainty in economic evaluation. British Medical Journal, 319 (7202): 120.
  9. Briggs A., Claxton K., Sculpherm M. (2007). Decision modeling for health economic evaluation, Oxford University Press Inc, New York.
  10. Cousien A., Train V.C., Deuffic-Burban S., Jauffret-Roustide M., Dhersin J.S., Yazdanpanah Y. (2016). Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology, 63(4): 1090-1101. DOI: 10.1002/hep.28227.
  11. European Association of the Study of the Liver (2014). EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol., 60(2): 392-420. DOI: 10.1016/j.jhep.2013.11.003.
  12. European Association of the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: final updates of the series.
  13. J. Hepatol., 73: 1170-1218.
  14. Fagiuoli S., Ravasio R., Lucà M.G., Baldan A., Pecere S., Vitale A., Pasulo L. (2015). Management of hepatitis C infection before and after liver transplantation. World J. Gastroenterol., 21(15): 4447-4456. DOI: 10.3748/wjg.v21.i15.4447.
  15. Gardini I., Bartoli M., Conforti M., Mennini F.S., Marcellusi A., Lanati E. (2016). HCV – estimation of the number of diagnosed patients eligible for the new anti-HCV therapies in Italy. Eur. Rev. Med. Pharmacol. Sci., 20 (Suppl. 1): 7-10.
  16. Gardini I., Bartoli M., Conforto M., Mennini F.S., Marcellusi A. (2019). Estimation of the number of HCV-positive patients in Italy. PLoS One, 31: 14.
  17. Gountas I., Sypsa V., Anagnostou O., Martin N., Vickerman P., Kafetzopoulos E., Hatzakis A. (2017). Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting? Addiction, 112(7): 1290-1299. DOI: 10.1111/add.13764.
  18. Grebely J., Dore G.J. (2017). Treatment of HCV in persons who inject drugs: treatment as prevention. Clin. Liver Dis., 9(4): 77-80.
  19. Grebely J., Dore G.J., Morin S., Rockstroh J.K., Klein M.B. (2017). Elimination of HCV as a public health concern among people who inject
  20. drugs by 2030 - What will it take to get there? J. Int. AIDS Soc., 20(1): 22146. DOI: 10.7448/IAS.20.1.22146.
  21. Hatzakis A., Lazarus JV., Cholongiatas E., Baptista-Leite R., Boucher C., Busoi C.S., Deuffic-Burban S., Chhatwal J., Esmat G., Hutchinson S., Malliori M.M., Maticic M., Mozalevskis A., Negro F., Papandreou G.A., Papatheodoridis G.V., Peck-Radosavljevic M., Razavi H., Reic T., Schatz E., Tozun N., Younossi Z., Manns M.P. (2020). Securing sustainable funding for viral hepatitis elimination plans. Liver International Liver Int., 40: 260-270.
  22. Hellard M., Scott N., Sacks-Davis R., Pedrana A. (2018). Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond. J. Hepatol., 68(3): 383-385. DOI: 10.1016/j.jhep.2017.12.004.
  23. Italian Budget Law (2019). Law n° 145, 30 December 2018, art. 1, c. 291. Official Gazette, 31 December 2018.
  24. Heimbach J.K. (2017). Overview of the updated ASSLSD guidelines for the management of HCC. Gastroenterol. Hepatol., 13(12): 751-753.
  25. Hickman M., Dillon J.F., Elliot L., De Angelis D., Vickerman P., Foster G., Donna P., Eriksen A., Flowers P., Golberg D., Hollingworth W., Ijaz S., Liddell D., Mandal S., Martin N., Beer L.S.Z., Drysdale K., Fraser H., Glass R., Graham L., Gunson R.N., Hamilton E., Harris H., Harris M.,
  26. Harris R., Heinsbroek E., Hope V., Horwood J., Inglis S.K., Inees H., Lan A., Meadows J., McAlley A., Metcalfe C., Migchelsen S., Murray A.,
  27. Myring G., Palmateer N.E., Presanis A., Radley A., Ramsay M., Samartsidis P., Simmons R., Sinka K., Vost G., Ward Z., Whiteley D., Yeung A., Hutchinson S.J. (2019). Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who
  28. inject drug (EPIToPE). A natural expterimental (protocol). BMJ Open, 29, 9(9): e029538. DOI: 10.1136/bmjopen-2019-029538.
  29. Kondili L.A., Romano F., Rolli F.R., Ruggeri M., Rosato S., Brunetto M.R., Zigno A.L., Ciancio A., Di Leo A., Raimondo G., Ferrari C., Taliani G., Borgia G., Santantonio T.A., Blanc P., Gaeta G.B., Gasbarrini A., Chessa L., Erne E.M., Villa E., Ieluzzi D., Russo F.P., Andreone P., Vinci M., Coppola C., Chemello L., Madonia S., Veucchi G., Persico M., Zuin M., Puoti M., Alberti A., Nardone G., Massari M., Montalto G., Foti G., Rumi M.G., Quaranta M.G., Cicchetti A., Craxi A., Vella S., Piter Collaborating G. (2017). Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort. Hepathology, 66: 1814-1825.
  30. Kondili L.A., Robbins S., Blach S., Gamkrelidze I., Zignego A.L., Brunetto M.R., Raimondo G., Taliani G., Iannone A., Russo F.P., Santantonio T.A., Zuin M., Chessa L., Blanc P., Puoti M., Vinci M., Erne E.M., Strazzabosco M., Massari M., Lampertico P., Rumi M.G., Federico A., Orlandini A., Cianciao A., Borgia G., Andreone P., Caporaso N., Persico M., Ieluzzi D., Madonia S., Gori A., Gasbarrini A., Coppola C., Brancaccio G., Andriulli A., Quarante M.G., Montilla S., Razavi H., Melazzini M., Vella S., Craxi A., Piter Collaborating Group (2018). Forecasting Hepatitits C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? Liver International, 38: 2190-98.
  31. Kondili L.A., Gamkrelidze I., Blach S., Marcellusi A., Galli M., Petta S., Puoti M., Vella S., Razavi H., Craxi A., Mennini F.S., Piter Collaborating Group (2020). Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver International, 40: 1545-1555.
  32. Kondili L.A., Mennini F.S., Andreoni M., Babudieri S., Gardini I., Rossi A., Russo F.P., Nava F.A., Vella S. (2020). Verso una politica sanitaria di screening e linkage to care per l’eliminazione dell’infezione da epatite C in Italia. Le Infezioni in Medicina, Speciale 2: 5-28.
  33. Konerman M.A., Lok A.S. (2016). Hepatitis C treatment and barriers to eradication. Clin. Transl. Gastroenterol., 7(9): e193. DOI: 10.1038/ctg.2016.50.
  34. Lazarus J.V., Sperle I., Maticic M., Wiessing L. (2014). A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infect. Dis., 14 (Suppl. 6): S16. DOI: 10.1186/1471-2334-14-S6-S16.
  35. Lee M.H., Yang H.I., Yuan Y., L’Italien G., Chen C.J. (2014). Epidemiology and Natural History of Hepatitis C virus infection. World J. Gastroenterol., 20(28): 9270-9280. DOI: 10.3748/wjg.v20.i28.9270.
  36. Libro bianco della Gastroenterologia Italiana (2014).
  37. Magiorkinis G., Sypsa V., Magiorkinis E., Paraskevis D., Katsoulidou A., Belshaw R., Fraser C., Pybus O.G., Hatzakis A. (2013). Integrating
  38. phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PloS Comput. Biol., 9(1): e1002876. DOI: 10.1371/journal.pcbi.1002876.
  39. Marcellusi A., Viti R., Capone A., Mennini F.S. (2015). The economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness model. Eur. Rev. Med. Pharmacol. Sci., 19(9): 1610-1620.
  40. Marcellusi A., Viti R., Mecozzi A., Mennini F.S. (2016). The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach. Eur. J. Health Econ., 17(2): 139-147. DOI: 10.1007/s10198-014.0660-y.
  41. Marcellusi A., Viti R., Damele F., Camma C., Taliani G., Mennini F.S. (2016). Early treatment in HCV: is it a cost-utility option from the Italian perspectives? Clin Drug Investig., 36: 661-672.
  42. Marcellusi A., Viti R., Kondili L.A., Rosato S., Vella S., Mennini F.S., & PITER Collaborating group, available at (2019). Economic consequences of investing in anti-hcv antivial treatment from the Italian NHS perspective: a real world-based analysis of PITER data. Pharmacoeconomics, 37(2): 255-266.
  43. Martin N.K., Vickerman P., Grebely J. et al. (2013). Hepatitis C virus treatment for prevention among people who inject drugs: modeling
  44. treatment scale-up in the age of direct-actin antivirals. Hepathology, 58(5): 1598-1609.
  45. Maticic M. (2018). Presentation at 2nd European Union (EU). HCV Policy summit.
  46. Mennini F.S., Marcellusi A., Andreoni M., Gasbarrini A., Salomone S., Craxi A. (2014). Health policy model: long-term predictive results associated with the management of hepatitic C virus-induced diseases in Italy. Clinicoecon. Outcomes Res., 6: 303-310. DOI: 10.2147/CEOR.S62092.
  47. Metzig C., Surey J., Francis M., Conneely J., Abubakar I., White P.J. (2017). Impact of hepatitis C treatment as prevention for people who inject drugs is sensitive to contact network structure. Sci Rep., 7(1): 1833.
  48. Molinaro S., Resce G., Alberti A., Andreoni M., D’Egidio P.P.F., Leonardi C., Nava F.A., Pasqualetti P., Villa S. (2019). Barriers to effective management of hepatitis C virus in people who inject drugs: evidence form outpatient clinics. Drug Alcohol Rev., 38(6): 644-655. DOI: 10.1111/dar.12978.
  49. Nava F.A. (2019). I Ser.D. come presidi sul territorio: il ruolo dei Servizi nell’eliminazione di HCV. Quaderno di ReAdfiles, Suppl. 2, anno 20: 10-15.
  50. Nava F.A., Alberti A., Andreoni M., Babudieri M., Barbarini G., D’Egidio P.F., Leonardi C., Lucchini A. (2018a). For a program of eradication of hepatitis C in the population at risk (drug users and convicts). Acta Biomed., 89 (Suppl. 10): 33-41. DOI: 10.23750/abm.v89i10-S.7968.
  51. Nava F.A., Lucchini A., Trevisi L. (2018b). Modello integrato di presa in carico del PWID con HCV: ritorno di salute e costi evitabili per il Sistema Sanitario. ReAdfiles, 19: 35-38.
  52. Nava F.A., Lucchini A., Riglietta M., Cammarata L., Fasciani P., Tavanti G., Trotta P., Trevisi L. (2020a). Barriers for HCV treatment in Italian Drug Abuse Service: data from a multicentric observational study (SCUDO Project). Mission, Italian Quarterly Journal of Addiction, 54: 24-28.
  53. Nava F.A., Chiesa A., Strepparola G., Pennisi G., Vitali R.G., Trevisi L., Lucchini A. (2020b). The earlier the better. The cost of health services in treating PWIDs with chronic hepatitis C: results from a non-interventional study. Mission, Italian Quarterly Journal of Addiction, 54: 44-49.
  54. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., Degenhardt L. (2011). Global epidemiology of hepatitis B and hepathitis C in people who inject drugs: results of systematic review, Lancet, 378: 571-583.
  55. Polaris Observatory (2019). October 2.
  56. Ponziani F.R., Gasbarrini A., Pompili M., Burra P., Fagiuoli S. (2011). Management of hepatitis C virus infection recurrence after liver transplantation: an overview. Transplant Proc., 43(1): 291-295. DOI: 10.1016/j.transproceed.2010.09.102.
  57. Ponziani F.R., Mangiola F., Binda C., Zocco M.A., Gasbarrini A., Flore R. (2017). Future of liver disease in the era of directing antivirals for the treatment of hepatitis C. World J. Hepatol., 9(7): 352-367. DOI: 10.4254/wjh.v9.i7.352.
  58. Razavi H. (2018). HCV elimination in Europe: burden pathways and cost. Presentation at European Union (EU) HCV Policy summit.
  60. Relazione annuale al Parlamento sullo stato delle tossicodipendenze (2020). Availabe from:
  61. Rossi C., Butt Z.A., Wong S., Buxton J.A., Islam N., Yu A., Darvishian M., Gilbert M., Wong J., Chapinal N., Binka M., Alvarez M., Tyndall M.W., Krajden M., Janjua N.Z. (2018). Hepatitis Testers Cohort Team. J. Hepathol., 69(5): 1007-1014.
  62. Ruggeri M., Coretti S., Romano F., Kondili L.A., Vella S., Cicchetti A. (2018). Economic evaluation of the hepatitis C virus treatment extension to earlystage fibrosis patients: evidence from the PITER real-world cohort. Value Health, 21(7): 783-791.
  63. Scott N., Iser D.M., Thompson A.J., Doyle J.S., Hellard M.E. (2016). Costeffectiveness of treating chronic hepatitis C virus direct-acting antivirals in people who inject drugs in Australia. J. Gastroenterol. Hepathol., 31(4): 872-882. DOI: 10.1111/jgh.13223.
  64. Stanaway J.D., Flaxman A.D., Naghavi M., Fitzmaurice C., Vos T., Abubakar I., Abu-Raddad L.J., Assadi R., Bhala N., Cowie B., Forouzanfour M.H., Groeger J., Hanafiah K.M., Jacobsen K.H., James S.L., MacLachlan J., Malekzadeh R., Martin N.K., Mokdad A.A., Mokdad A.H., Murray C.J.L., Plass D., Rana S., Rein D.B., Richardus J.H., Sanabria J., Saylan M., Shahraz S., So S., Vlassov V.V., Weiderpass E., Wiersma S.T., Younis M., Yu C., El Sayed Zaki M., Cooke G.S. (2016). The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet, 388(10049): 1081-1088. DOI: 10.1016/S0140-6736(16)30579-7.
  65. Stevens E.R., Nucifora K.A., Hagan H., Jordan A.E., Uyei J., Khan B., Dombrowski K., des Jarlais D., Braithwaite R.S. (2019). Cost-effectiveness and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population. Clin. Infect. Dis., Jun 10, 70(12): 2652-2662 726. [Epubahead of print] DOI: 10.1093/cid/ciz726.
  66. Stroffolini T., D’Egidio P.F., Aceti A., Filippini P., Puoti M., Leonardi C., Almasio P.L., DAVIS Drug Addicted, HCV Prevalence in Italy an Epidemiological, Observational, Cross-Sectional, Multicenter Study participating centers (2012). Hepatitis C virus infection among drug addicts in Italy. J. Med. Virol., 84(10): 1608-1612. DOI: 10.1002/jmv.23370.
  67. Taylor M. (2019). What is sensitivity analysis? Newmarket, UK: Hayward Medical Communications. Available from:
  68. Taherkhani R., Farshadpour F. (2017). Global elimination of hepatitits C virus infection: progress and the remaining challenges. World J. Hepathol., 9(33): 1239-1252. DOI: 10.4254/wjh.v9.i33.1239.
  69. van Santen D.K., de Vos A.S., Matser A., Willemse S.B., Lindenburg K., Kretzschmar M.E., Prins M., de Wit G.A. (2016). Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands. PLoS One, 11(10): 0163488. DOI: 10.1371/journal.pone.0163488.
  70. Vietri J., Prajapati G., El Khoury A.C. (2013). The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries. BMC Gastroenterol., 13: 16. DOI: 10.1186/1471-230X-13-16.
  71. Vold J.H., Aas C., Leiva R.A., Vickerman P., Chalabianloo F., Loberg E.M., Johansson K.A., Fadnes L.T. (2019). Integrated care of severe infection diseases to people with substance use disorder. BMC Infect. Dis., 19(1): 306, DOI: 10.1186/s12879-019-4598-7.
  72. WHO (2016). Global report on access to hepatitis C treatment - Focus on overcoming barriers.
  73. WHO (2017). Global Hepatitis Report;


Caricamento metriche ...